Gain Therapeutics' (GANX) Buy Rating Reiterated at BTIG Research

Key Points

• BTIG Research has reiterated a "buy" rating for Gain Therapeutics (NASDAQ: GANX) with a price target of $9.00, indicating a potential upside of 411.36% from its current price.
• Other analysts have varied projections, with Roth Capital lowering its price target from $7.00 to $6.00, while HC Wainwright maintains a buy rating with a target of $8.00, contributing to a consensus rating of "Buy."
• Gain Therapeutics reported a loss of ($0.19) earnings per share for the last quarter, missing the consensus estimate and projecting to post -1 earnings per share for the current fiscal year.

BTIG Research reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX - Free Report) in a research report released on Monday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

Several other brokerages have also commented on GANX. Roth Capital reduced their price objective on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Thursday, July 3rd. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $8.00.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock traded down $0.06 during trading on Monday, hitting $1.66. 508,667 shares of the stock traded hands, compared to its average volume of 588,973. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09. The stock has a market cap of $59.68 million, a price-to-earnings ratio of -2.63 and a beta of 0.14. The firm's fifty day moving average is $1.69 and its 200-day moving average is $1.82. Gain Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Research analysts expect that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics in the 4th quarter worth approximately $65,000. Kovitz Investment Group Partners LLC purchased a new stake in Gain Therapeutics in the 1st quarter worth approximately $91,000. Northern Trust Corp lifted its holdings in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after buying an additional 39,642 shares during the period. Dauntless Investment Group LLC purchased a new stake in Gain Therapeutics in the 1st quarter worth approximately $240,000. Finally, Marshall Wace LLP lifted its holdings in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock worth $498,000 after buying an additional 80,407 shares during the period. Hedge funds and other institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.